[{"id":5880,"regimens":[{"id":10984,"duration":{"id":5042,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7274,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10984},{"id":7275,"answer":"In a novel combination with another drug","answer_other":"","regimen":10984}],"created":"2020-09-10T20:54:38.668514Z","updated":"2020-09-10T21:13:20.452605Z","dose":"420 mg","frequency":"OD","route":"","severity":"Outpatient","severity_detail":null,"comments":null,"report":5880},{"id":10985,"duration":{"id":5043,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7276,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10985},{"id":7277,"answer":"In a novel combination with another drug","answer_other":"","regimen":10985}],"created":"2020-09-10T20:54:38.676565Z","updated":"2020-09-10T21:13:20.420225Z","dose":"","frequency":"","route":"","severity":"Outpatient","severity_detail":"","comments":null,"report":5880},{"id":10986,"duration":{"id":5044,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":7278,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10986},{"id":7279,"answer":"In a novel combination with another drug","answer_other":"","regimen":10986}],"created":"2020-09-10T20:54:38.683137Z","updated":"2020-09-10T21:13:20.426285Z","dose":"","frequency":"","route":"","severity":"Outpatient","severity_detail":"","comments":null,"report":5880}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7697,"answer":"Clinical assessment","answer_other":"","report":5880}],"how_diagnosis":[{"id":13077,"answer":"Clinical assessment","answer_other":"","report":5880},{"id":13078,"answer":"Imaging","answer_other":"","report":5880},{"id":13079,"answer":"PCR","answer_other":"","report":5880}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3810,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5880}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":184,"answer":"White","answer_other":""}],"created":"2020-09-10T20:52:52.371008Z","updated":"2020-09-10T21:13:20.404358Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32302379","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8373]},{"id":5881,"regimens":[{"id":10987,"duration":{"id":5045,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7280,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10987}],"created":"2020-09-10T21:06:51.844062Z","updated":"2020-09-10T21:22:17.214146Z","dose":"420 mg","frequency":"OD","route":"","severity":"Outpatient","severity_detail":null,"comments":null,"report":5881}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7698,"answer":"Clinical assessment","answer_other":"","report":5881}],"how_diagnosis":[{"id":13080,"answer":"Clinical assessment","answer_other":"","report":5881},{"id":13081,"answer":"Imaging","answer_other":"","report":5881},{"id":13082,"answer":"PCR","answer_other":"","report":5881}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3811,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5881}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":185,"answer":"White","answer_other":""}],"created":"2020-09-10T21:05:18.560053Z","updated":"2020-09-10T21:22:17.183232Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32302379","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8373]},{"id":5882,"regimens":[{"id":10988,"duration":{"id":5046,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7281,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10988}],"created":"2020-09-10T21:18:17.036549Z","updated":"2020-09-10T21:28:16.469513Z","dose":"420 mg","frequency":"OD","route":"","severity":"Outpatient","severity_detail":"","comments":null,"report":5882}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7699,"answer":"Clinical assessment","answer_other":"","report":5882}],"how_diagnosis":[{"id":13083,"answer":"Clinical assessment","answer_other":"","report":5882},{"id":13084,"answer":"Imaging","answer_other":"","report":5882},{"id":13085,"answer":"PCR","answer_other":"","report":5882}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3812,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5882}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":186,"answer":"White","answer_other":""}],"created":"2020-09-10T21:17:30.255781Z","updated":"2020-09-10T21:28:16.460449Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32302379","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"71-80 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8373]},{"id":5884,"regimens":[{"id":10991,"duration":{"id":5049,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7286,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10991}],"created":"2020-09-12T05:11:26.858758Z","updated":"2020-09-12T05:19:34.906518Z","dose":"420 mg","frequency":"OD","route":"PO","severity":"Outpatient","severity_detail":"","comments":null,"report":5884}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7700,"answer":"Clinical assessment","answer_other":"","report":5884}],"how_diagnosis":[{"id":13089,"answer":"Clinical assessment","answer_other":"","report":5884},{"id":13090,"answer":"Imaging","answer_other":"","report":5884},{"id":13091,"answer":"PCR","answer_other":"","report":5884}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3816,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5884}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":188,"answer":"White","answer_other":""}],"created":"2020-09-12T05:06:05.693790Z","updated":"2020-09-12T05:19:34.899162Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 4","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://pubmed.ncbi.nlm.nih.gov/32302379/","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"Outpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[8373]},{"id":5885,"regimens":[{"id":10992,"duration":{"id":5050,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7287,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10992}],"created":"2020-09-12T05:21:32.064294Z","updated":"2020-09-12T05:28:00.598118Z","dose":"420 mg","frequency":"OD","route":"PO","severity":"Outpatient","severity_detail":"","comments":null,"report":5885}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7701,"answer":"Clinical assessment","answer_other":"","report":5885}],"how_diagnosis":[{"id":13092,"answer":"Clinical assessment","answer_other":"","report":5885},{"id":13093,"answer":"Imaging","answer_other":"","report":5885},{"id":13094,"answer":"PCR","answer_other":"","report":5885}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3817,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5885}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":189,"answer":"White","answer_other":""}],"created":"2020-09-12T05:20:46.014959Z","updated":"2020-09-12T05:28:00.590597Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 5","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://pubmed.ncbi.nlm.nih.gov/32302379/","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"5","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"Outpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"True","flagged":false,"other_coinfections":"","disease":630,"drugs":[8373]},{"id":5886,"regimens":[{"id":10993,"duration":{"id":5051,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8373,"name":"Ibrutinib","url":"cure-api2.ncats.io/v1/drugs/8373","rxNorm_id":null,"notes":null},"use_drug":[{"id":7288,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10993},{"id":7289,"answer":"In a novel combination with another drug","answer_other":"","regimen":10993}],"created":"2020-09-12T05:30:08.399293Z","updated":"2020-09-12T05:44:56.047699Z","dose":"420 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10994,"duration":{"id":5052,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":7290,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10994},{"id":7291,"answer":"In a novel combination with another drug","answer_other":"","regimen":10994}],"created":"2020-09-12T05:30:08.407027Z","updated":"2020-09-12T05:44:56.054723Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10995,"duration":{"id":5053,"approximate_duration":"3 days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":7292,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10995},{"id":7293,"answer":"In a novel combination with another drug","answer_other":"","regimen":10995}],"created":"2020-09-12T05:30:08.413333Z","updated":"2020-09-12T05:44:56.060483Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10996,"duration":{"id":5054,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":7294,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10996},{"id":7295,"answer":"In a novel combination with another drug","answer_other":"","regimen":10996}],"created":"2020-09-12T05:30:08.419673Z","updated":"2020-09-12T05:44:56.066261Z","dose":"400 mg","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886},{"id":10997,"duration":{"id":5055,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":8412,"name":"Immunoglobulins, Intravenous","url":"cure-api2.ncats.io/v1/drugs/8412","rxNorm_id":null,"notes":null},"use_drug":[{"id":7296,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10997},{"id":7297,"answer":"In a novel combination with another drug","answer_other":"","regimen":10997}],"created":"2020-09-12T05:37:51.904451Z","updated":"2020-09-12T05:44:56.071924Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":5886}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7702,"answer":"Clinical assessment","answer_other":"","report":5886}],"how_diagnosis":[{"id":13095,"answer":"Clinical assessment","answer_other":"","report":5886},{"id":13096,"answer":"Imaging","answer_other":"","report":5886},{"id":13097,"answer":"PCR","answer_other":"","report":5886}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3818,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5886}],"adverse_event_outcome":[{"id":29,"answer":"Life-threatening","report":5886}],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":190,"answer":"White","answer_other":""}],"created":"2020-09-12T05:28:37.435192Z","updated":"2020-09-12T05:44:56.039857Z","title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Case 6.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32302379,"doi":"10.1182/blood.2020006288","article_url":"https://pubmed.ncbi.nlm.nih.gov/32302379/","pub_year":2020,"published_authors":"Treon SP\r\nCastillo JJ\r\nSkarbnik AP\r\nSoumerai JD\r\nGhobrial IM\r\nGuerrera ML\r\nMeid K\r\nYang G","article_author_email":"Author email could not be found.","journal":"Blood","abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model. Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.","article_type":"Original","study_type":"Case Report","number_of_patients":6,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":true,"other_comorbid":"Waldenstrom macroglobulinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":"ICU/Critical Care","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":true,"adverse_events":"Azithromycin - wide QRS complex tachyarrhythmia, which was then stopped after 3 days","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Patient was on 140 mg/d of ibrutinib prior to hospitalization that was held upon admission; he experienced worsening hypoxia after ibrutinib was held and required mechanical ventilation, following which he was restarted on 420 mg/d of ibrutinib and showed rapid improvement in oxygenation.\r\n\r\nPatient also received mechanical ventilation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,8342,8373,8412,10776]}]